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The past decade has witnessed a major advance in the psychiatric treatment of the depressive disorders. For some thirty years since its introduction by Cerletti and Bini, electroconvulsive treatment (E.eT.) was the major therapeutic modality for the relief of the profound depressive states which were not amenable to psychotherapy, sedatives and amphetamines. With the advent of a number of chemotherapeutic agents, psychiatry is entering a phase where it may be possible to select a treatment of choice for depressions, depending on the characteristics of the disorder. Depression can occur as a temporary reaction to an emotional trauma, it may be present in a schizophrenic reaction or it may occur as a pathological entity in itself as in the endogenous depressions (20) . It has been difficult to establish unequivocal diagnostic or symptomatic criteria to serve as a guide for treatment. Although various therapeutic agents cut across diagnostic lines, there are those cases which are clinically similar but respond differently to the same treatment (12) . The former condition may be explained on the basis of a non-specificity of the treatment or a similar pathophysiology but with a dissimilar manifestation. The latter condition, i.e. the differential response, may be due to individual differences in the metabolism of a drug to an active metabolite (e.g. imipramine to desmethylimipramine) or a dissimilar pathophysiology with a common clinical syndrome. The situation is much the same in other diseases, e.g. hypertension and diabetes.
One feature which the therapies for depression have in common is that they exert an effect on the sympathetic nervous system. Plasma levels and excretion of catecholamines are increased after E.C.T. (28, 14) and there is an increase in sympathetic reactivity to stimulation by mecholvl (11) . Monoamine oxidase inhibitor; raise the level of catecholamines in the brain (25) and the antidepressant cyclicdibenzyl compounds (imipramine, amitriptyline) potentiate the action of norepinephrine (22) . Reserpine, which depletes the brain and peripheral sympathetics of monoamines, gives rise to a predominance of parasympathetic over sympathetic activity and can induce a depression in patients (22) . Reserpine also causes 'depressive-like' states in animals which can be reversed by restoring brain monoamine with dihydroxyphenylalamine (DOPA). However, DOPA is ineffective in depressed patients (13) .
The urinary excretion of catecholamines varies with different emotional states but, in spite of experimental and clinical data which indicate a relationship between the monoamines, electroshock, monoamine oxidase inhibitors and the antidepressant drugs, there is no evidence of an abnormality in the metabolism of norepinephrine or serotonin or the enzymes involved in their synthesis or disposition in depressions (5) . We therefore investigated the metabolism of infused H'-norepinephrine in patients with depression as well as other psychiatric illnesses.
Methods
Subjects for this study were selected from patients hospitalized at The Mount Sinai Hospital Institute of Psychiatry. All patients receive intensive psychotherapy by residents from three. to five times a week and are hospitalized for a maximum period of ninety days. The 550 Special Supplement :\IETABOLISM OF NOREPINEPHRINE S51 criterion used for the selection of subjects for this study was the presence of depression as one of the obvious manifestations of their illness regardless of the clinical diagnosis. The latter was arrived at by consensus of the resident treating the patient, the preceptor supervising the therapy, the ward chief and the senior author. A battery of psychological tests was administered to a patient only if the diagnosis was in doubt after several weeks of clinical observation. Patients were also rated with the Wechsler Depressive Rating Scale, which scores twenty-eight parameters most commonly associated with depression (27) . This instrument had certain limitations, e.g. in conditions where the mood is particularly labile as in the schizoaffective disorders and it did not differentiate between depression and apathy. Those patients who appear depressed, but are really in an apathetic state complain primarily of anxiety, or a lack of any feeling, rather than depression. Instead of relying on an absolute score, we used the test to arrive at a semi-quantitative measure of both the degree of depression and agitation or anxiety present in the patient. We then simply rated the patient according to the relatively dominant affective state. Therefore, all patients had a diagnosis according to the A.P.A. Diagnostic and Statistical Manual of Mental Disorders, and were rated as to whether the depression was greater than the agitation (or anxiety), equal to it or less. Clinically the intensity of either affective state was in the moderately severe to very severe range. There were no patients with only minimal depression or agitation.
After admission to the ward the patient was asked whether he wished to engage in this study after a complete explanation of the procedures were given to him. Over ninety-five per cent complied. The other five per cent were usually paranoid schizophrenics who refused to have an infusion. The patients received only barbituates or chloral hydrate for sedation if it was needed, and the dosage was held to a minimum. All patients received the regular ward diet supplemented with multivitamin preparations and an additional 500 mg. of Vitamin C, per os, daily. During the second week the patient was given an infusion of 1 millicurie of tritiated Ht-norepinephrine diluted with 100 ml. of 5 per cent dextrose. The infusion lasted thirty minutes and was generally done in the late morning or early afternoon. Urine specimens were collected immediately after the infusion and then at two-hour intervals for twelve hours. The final specimen consisted of all the urine voided between the twelfth and twenty-fourth hour. The concentration of radioactivity in the second twentyfour hours was generally too low for an accurate analysis of all metabolites.
The urine was collected without preservative and placed immediately after voiding into a refrigerator on the ward. All specimens were taken to the laboratory after 24 hours and worked up that day or placed on the deep freeze (_16 0 C) until used, which was generally within two or three days. Urine specimens kept in the deep freeze for three months showed no change, although a significant alteration in the composition of the tritiated metabolites did occur some time after this period. The nature and relative percentages of the metabolic products were determined with a high degree of accuracy by a new method developed in our laboratory which combines both paper electrophoresis and chromatography (9) . The initial step in this procedure consists of the paper electrophoresis in borate buffer of a concentrated aliquot of urine. This step achieves two orders of separation of the catecholamine metabolites. There is a separation of those metabolic products which still retain the amine group from those which have been attacked by monoamine oxidase; and there is also an almost complete differentiation of the individual metabolites, depending on the structural changes undergone by norepinephrine, i.e. methylation, conjugation or oxida-tion. A more detailed and accurate determination of the 'metabolic profile' is arrived at by paper chromatography of the various electrophoretic fractions after elution. Figure 1 is a typical curve of the characteristic change in the relative amounts of amine retaining and oxidized catecholamine metabolites excreted after an infusion of H'-norepinephrine. NjO is the ratio of the concentrations of metabolites retaining nitrogen (norepinephrine, normetanephrine and conjugates) to those which have been oxidized (vanillomandelic acid, 3-methoxy-4-hydroxyphenylglycol, dihydroxyphenylglycol, dihydroxymandelic acid and conjugates). As can be seen from the figure, the ratio of amines to deaminated products drops sharply after the infusion and then rises gradually to a plateau after 10-12 hours. Figure 2 shows the percentages of the metabolites in the urine collected over the first 24 hours. Normetanephrine is the principal amine and vanillomandelic acid the principal oxidized product. The flattening of both curves after 10-12 hours indicates a steady state of release of bound H'-norepinephrine from the tissues after equilibration with the endogenous pools.
Results
The metabolic pattern in the 12-24hour specimens of depressed patients is shown in Table I . As can be seen, there is a definite tendency towards an elevated NjO ratio in those patients in whom the depression was the prominent symptom and who were considered as having a primary depressive disorder. These patients had been diagnosed as manic- L>a depressive, depressed phase. We used this diagnosis instead of the all-encompassing endogenous depression in order to separate manic-depression from involutional psychosis. All of these patients had a history of recurrent depressions severe enough to necessitate hospitalization. Three patients had a history of manic episodes in addition to the depressions. The precipitating factors were minimal and were not commensurate with the intensity or duration of the depression. There was no evidence of a schizophrenic process during this or previous hospitalizations or in the patient's life history. Most of these patients showed the typical sad, despairing mood, psychomotor retardation, guilt, early morning insomnia, inability to start the day and the typical diurnal fluctuation. Patient M.E. had been hospitalized on four prior occasions for depression and when seen during her current admission had just swung from a depressed phase into a hypomanic episode. Except for this patient, the others showed a slowing in thinking and motor retardation. In those in whom anxiety was also present, the depressed affect preempted it as the primary symptom. The patients who were diagnosed as reactive depression had a history of severe current personal difficulties, which they had been unable to resolve, the severity of the depression was usually not as great as in the previous patients, they were still able to function, albeit poorly, anxiety was greater, and there was no slowing up in the areas of thinking and acting. They were still actively struggling to resolve a conflict, which was easily identi·fied and commensurate with their distress. This was their first hospitalization for depression. There was no previous history of intense or prolonged depressive episodes in their lives, although they tended to become depressed under stressful life situations. The differential diagnosis between the two types of depressions is often difficult to make because of many similarities, including the characteristic recurrences in both. Table I however, indicates that these patients also showed a shift in the direction of the manic-depressive group in terms of the relative increase of amine-retaining metabolites in the late urine specimens. Another striking feature seen in Table I is that both the patients with involutional psychosis and schizophrenia had N/O values in the normal range. These involutional psychotic patients in our series were primarily irritable, restless and agitated. They had been treated in the past unsuccessfully with antidepressant drugs.
Electroshock Treatment-Four patients were given a course of electroshock treatment. Two had been diagnosed as manic depressives and two as involutional psychotics of the agitated, depressed type. All patients received 10 E.e.T. and made a good response. Patients ].B. and B.M. who were diagnosed as manic depressive were still in remission four and six months after E.e.r. and no tranquillizer or antidepressive medication was required during this period. They showed elevated N/O ratios before treatment, 0.84 and 0.86, which dropped to 0.49 and 0.50 after treatment. The two patients M.e. and W.R. with diagnoses of involutional psychosis had a remission after E.e.r. for approximately three weeks when symptoms of anxiety and agitation returned. The N/O ratios were in the normal range before treatment and did not change significantly after treatment. Although this type of relapse after E.e.T. often responds to another course, we ratio four weeks later showed it to be the same value as one week after treatment. Another patient (RM., age 45, Table I) , with a long-standing history of manic depressive disease who had received five courses of E.CT. over a period of fifteen years, was treated during her recent hospitalization by intensive supportive psychotherapy alone. She had a spontaneous, partial remission and was well enough to be discharged after six weeks. The NjO ratio dropped from 0.79 to 0.68. Tranquillizers and Antidepressant Drugs-The changes in the distribution of H"-norepinephrine metabolites in patients who were placed on either chlorpromazine, imipramine, amitriptyline or chlordiazepoxide are shown in Tables IV and V. It is seen that in spite of differences in the chemical structure they all have in common the effect of altering the composition of the metabolites in the 12-24hour specimen by significantly elevating the NjO ratio. The patients received the particular drug in divided doses for at least one week before the norepinephrine infusion. It is seen from Table IV that when imipramine was combined with chlorpromazine, it had the effect of attenuating the change in NjO ratio seen when chlorpromazine was given alone. This antagonism was noted in each of the two-hour urine specimens as well as the 12-24-hour one. Figure 3 compares the sequence of changes in urine specimens collected at various intervals for 24 hours, without medication and when the patient was taking chlorpromazine. It can be seen that the greatest effect occurs with the later urine specimens.
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Discussion
In a comprehensive and critical review by Kety of the various investigations into the metabolism of epinephrine in both normal and psychotic individuals, he found no evidence of any differences in the metabolic products between these groups (16) . In these and other studies either H"-or C'-epinephrine was infused, the urine was collected for the next 24-48 hours and analyzed for the distribution of the various metabolites. This technique is useful in determining whether there is an alteration in a major metabolic pathway of the catecholamines or the production of an abnormal metabolite. It has been shown by Axelrod (1) that following the infusion of norepinephrine into an animal, it is rapidly bound in the tissues from which it is released in two or more stages. The amine leaves the tissues rapidly at first and then at a slower rate over a period of days. Trendelenberg (26) , Kopin (17) and Chidsey (8) have shown that norepinephrine is present in more than one endogenous pool in the sympathetic nervous system and that there are differences in the release and metabolism of these pools. Infused H 3 _ norepinephrine mixes initially with a mobile pool of norepinephrine and gradually becomes equilibrated with a more firmly-bound pool. We decided to focus our attention on the metabolites present in the urine between 12 and 24 hours after an infusion, when the tritiated excretion products are derived primarily from the tritiated norepinephrine which had been mixed with the endogenous pools. It is only at this stage that the tritiated amine actually behaves as a tracer in reflecting the metabolism of unlabelled sympathetic norepinephrine.
The serial collection of urine after an infusion of Ht-norepinephrine reveals a temporal change in the proportions of those metabolites retaining nitrogen and those which have been oxidized. The metabolic pattern becomes constant after 10 to 12 hours. Since the intracellular transport and binding are reported to be stereo-specific (18) the metabolites in the early urine specimens are derived primarily from the dextro isomer. The relatively high proportion of oxidized products can be accounted for by monoamine oxidase attack due to the lack of protective binding as occurs with the levo form. After 10 or 12 hours the tagged norepinephrine is released from the nerve endings in response to nerve stimuli and is metabolized primarily by catechol-Omethyltransferase (2) . It has been shown by Kopin that norepinephrine released by tyramine gives rise to a greater amount of normetanephrine than the reserpinereleased amine (19) . Tyramine releases norepinephrine from the mobile pool. The fact that the relative amount of normetanephrine tends to increase with time would indicate that the norepinephrine is being released via the mobile pool into the surrounding tissues (see Figures 1 and 2) . The increase in the proportion of normetanephrine seen in patients with manic depressive depression can have several explanations. It may be due to an increased rate of methylation of released norepinephrine, a shift in equilibrium between pools in the direction of the mobile pool, a greater rate of release from the mobile pool, or a decreased rate of oxidation by amine oxidase. The last explanation, however, would stand in opposition to the clinical and experimental observations that the monoamine oxidase inhibitors are effective in depressions presumably by interfering with monoamine oxidation. It is therefore paradoxical to find what appears to be decreased oxidation of amines in certain depressions which are known to respond to MAO inhibitor therapy. However, the mechanism of action of MAO inhibitors in relieving depressions by primarily inhibiting the oxidation of norepinephrine has been challenged by Axelrod's evidence that MAO inhibitors can block the release of norepinephrine from its storage sites (3) . The increase in normetanephrine relative to the oxidized products would suggest that it is being formed at a rate greater than it is oxidized by MAO. However, it has also been shown by Feldstein that there is no alteration in MAO activity in depressed patients (10) .
Normetanephrine is active at adrenergic receptor sites although it is far weaker than norepinephrine (7) . It therefore can probably act as an antagonist to norepinephrine. It is possible that in the pathological depression normetanephrine interferes with the action of norepinephrine at central as well as peripheral sites. This, of course, is based on the assumption that the physiological and metabolic disposition of norepinephrine in the brain is similar to that in the peripheral sympathetic nervous system. It is apparent from Table I that the endogenous depressions are a heterogenous group chemically and clinically, and that the manic depressive disorder has a metabolic change associated with it that was not present in our group of patients with involutional psychosis or schizophrenia with depression. The reactive depressions in this study showed an increase in normetanephrine relative to vanillomandelic acid in the same direction as the manic depressives but to a lesser degree. This is in accord with many clinical observations which suggest that these depressions, often recurrent, may be milder forms of manic-depressive disease. A surprising finding was the absence of a change in the metabolic pattern with involutional psychosis. Our group of patients became ill for the first time in the sixth or seventh decade of life with what appeared to be their first depression. This was unlike the history of those patients with a primary depressive disorder, who had had multiple depressions starting in the third and fourth decade or earlier. It is often suggested that involutional psychosis is an atypical schizophrenic disorder appearing late in life. Our findings certainly indicate that the norepinephrine metabolic pattern in those with an involutional psychosis is dissimilar to that found in the manic-depressive depressions. Kallman has shown that, on genetic considerations, involutional psychosis is more closely related to schizophrenia than to manicdepression (15) .
It can be seen by comparing Tables II  and III with IV and V that the mechanism of action of E.C.T. is different from that of the cyclicdibenzyl drugs, in so far as the effect on the excretion patterns of norepinephrine metabolites is concerned. E.C.T. will change the pattern of the metabolites to a normal one in those patients in whom there is an elevated N/O ratio. The antidepressants (as well as chlorpromazine and chlordiazepoxide) raise the relative proportion of excreted normetanephrine. This would suggest that E.C.T. may be a specific treatment for certain types of depressions if we base this conclusion on the reversal of the abnormal catecholamine metabolic pattern. Of course, this logic only holds if the relationship between catecholamine metabolism and primary depression is a close one, as appears to be the case with the manic-depressive group.
The fact that chlorpromazine raises the relative normetanephrine values may explain the report that this drug will often precipitate a frank depressive state in predisposed patients (24) . The upward shift in NjO ratio after certain tranquillizers (Table IV) may be revealing a common denominator of their mode of action. Chlorpromazine lowers the urinary excretion of vanillomandelic acid in normal subjects without any effect on the rate of creatinine excretion (21) . This finding, taken together with the elevated N/O ratio indicates a significant alteration in the disposition of endogenously released norepinephrine after chlorpromazine. One possible mechanism may be a decreased uptake of norepinephrine as shown by Axelrod (4) .
There is a seeming contradiction in the finding that the cyclicdibenzyl drugs, although efficacious in some depressions, also raised the N/O ratio. It is conceivable that their effectiveness in sen-sitizing adrenergic receptors to norepinephrine (23) and their anticholinergic action (6) overcome any possibly depressant properties related to the elevation of the N/O ratio. It has been noted clinically that these drugs do not relieve depressions in the manner accomplished by MAO inhibitor or E.C.T. There is a general lessening of the intensity of the depressive symptoms rather than the removal of the depression per se. The implication of raised tissue levels of normetanephrine and its antagonism to norepinephrine at adrenergic receptors as a possible mechanism in certain depressions is, of course, purely speculative at this point.
Summary
The metabolism of infused Ht-norepinephrine was studied in twenty psychiatric patients with depression. A difference was found in the metabolism in those patients classified as manic-depressive in that they tended to have a definite increase in the urine in the proportion of those metabolites which retain the amine group as compared to the metabolites which had undergone oxidative deamination (N/O ratio). The main amine metabolite was normetanephrine while the main oxidized metabolite was vanillomandelic acid. Patients diagnosed as reactive depression also tended to have an elevated NIO ratio, but to a lesser degree than the manic-depressives. Those patients with involutional psychosis or schizophrenia with depression did not differ from the normals in the amine metabolism.
E.C.T. appears to be especially effective in those patients with an abnormal amine pattern and it also corrects the disturbance in the metabolism. Chlorpromazine, imipramine, amitriptyline and chlordiazepoxide cause a marked change in the metabolic pattern of norepinephrine.
Evidence is cited which suggests that the altered norepinephrine metabolism may result in an elevation of normetanephrine at synaptic sites which could antagonize the action of sympatheticallyreleased norepinephrine.
